

Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption

NCT05232942

Status	RECRUITING
Sponsor	Hospital Clínico Universitario de Valladolid
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (7)

- Patients diagnosed with episodic or chronic migraine according to criteria of the International Classification of Headache Disorders, 3rd Edition.
- Patients who previously received treatment with a monoclonal antibody (mAbs) against CGRP or its receptor at the discretion of their usual neurologist, according to the standard of care and local guidelines.
- Patients who experienced a positive therapeutic response to mAbs.
- Patients that received the treatment for a minimum of 3 months.
- Age between 18 and 65 years.
- ... and 2 more (see full listing online)

Exclusion (5)

- Presence of another type of concomitant chronic headache, defined by frequency greater than 15 days per month in the previous three months, except for medication overuse headache.
- Patients planning to start another treatment with a possible preventive effect according to the national clinical practice guidelines within the six following weeks after their inclusion in the present study for any therapeutic indication.
- Patients who started another treatment with a possible preventive effect according to the national clinical practice guidelines within the previous six weeks of the evaluation of the inclusion in the present study.
- Pregnancy or breastfeeding.
- Patients who discontinued treatment with the monoclonal antibody due to an adverse effect and not to an efficacy response.

Locations (1 total)

Hospital Clínico Universitario de Valladolid, Valladolid, Spain